Moneycontrol PRO
HomeNewsBusinessStocksTorrent Pharmaceuticals shares fall 2.01% in Wednesday's session

Torrent Pharmaceuticals shares fall 2.01% in Wednesday's session

Shares of Torrent Pharmaceuticals declined by 2.01% to Rs 3,570 in Wednesday's session, reflecting a shift in investor sentiment.

September 10, 2025 / 13:51 IST
Disclaimer This is an AI-assisted live blog with updates from multiple sources Disclaimer
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Shares of Torrent Pharmaceuticals declined by 2.01% to Rs 3,570 in Wednesday's session. The stock trading lower compared to its previous close.

    Torrent Pharmaceuticals is included as one of the stocks in the Nifty Next 50 index.

    Here is a summary of Torrent Pharmaceuticals' financial performance:

    Consolidated Financials (Quarterly)

    HeadingJun 2024Sep 2024Dec 2024Mar 2025Jun 2025
    RevenueRs 2,859.00 CroreRs 2,889.00 CroreRs 2,809.00 CroreRs 2,959.00 CroreRs 3,178.00 Crore
    Net ProfitRs 457.00 CroreRs 453.00 CroreRs 503.00 CroreRs 498.00 CroreRs 548.00 Crore
    EPS13.5113.3714.8814.7116.19

    The revenue for Torrent Pharmaceuticals has shown a fluctuating pattern over the past five quarters, with a recent increase. The revenue increased from Rs 2,859 Crore in June 2024 to Rs 3,178 Crore in June 2025. Similarly, the net profit has also experienced fluctuations, with a increase from Rs 457 Crore in June 2024 to Rs 548 Crore in June 2025. The EPS has followed a similar trend, rising from 13.51 in June 2024 to 16.19 in June 2025.

    Consolidated Financials (Yearly)

    Heading20212022202320242025
    RevenueRs 8,004.57 CroreRs 8,508.04 CroreRs 9,620.15 CroreRs 10,727.84 CroreRs 11,516.09 Crore
    Net ProfitRs 1,251.88 CroreRs 777.18 CroreRs 1,245.23 CroreRs 1,656.38 CroreRs 1,911.25 Crore
    EPS73.9845.9336.7948.9456.47
    BVPS344.90351.75183.13202.57224.27
    ROE21.4413.0520.0924.1525.17
    Debt to Equity0.830.670.850.570.40

    The revenue for Torrent Pharmaceuticals has consistently increased over the past five years, rising from Rs 8,004.57 Crore in 2021 to Rs 11,516.09 Crore in 2025. The net profit has also shown a significant increase, growing from Rs 1,251.88 Crore in 2021 to Rs 1,911.25 Crore in 2025. The EPS has followed a similar upward trajectory, increasing from 73.98 in 2021 to 56.47 in 2025. The Return on Equity (ROE) has also increased from 21.44 in 2021 to 25.17 in 2025. The debt-to-equity ratio has decreased from 0.83 in 2021 to 0.40 in 2025.

    Consolidated Income Statement (Yearly)

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    SalesRs 11,516 CroreRs 10,727 CroreRs 9,620 CroreRs 8,508 CroreRs 8,004 Crore
    Other IncomeRs 23 CroreRs 57 CroreRs 45 CroreRs 196 CroreRs 56 Crore
    Total IncomeRs 11,539 CroreRs 10,785 CroreRs 9,665 CroreRs 8,704 CroreRs 8,061 Crore
    Total ExpenditureRs 8,614 CroreRs 8,080 CroreRs 7,484 CroreRs 7,223 CroreRs 6,182 Crore
    EBITRs 2,925 CroreRs 2,705 CroreRs 2,180 CroreRs 1,480 CroreRs 1,879 Crore
    InterestRs 252 CroreRs 353 CroreRs 333 CroreRs 255 CroreRs 352 Crore
    TaxRs 761 CroreRs 695 CroreRs 601 CroreRs 448 CroreRs 274 Crore
    Net ProfitRs 1,911 CroreRs 1,656 CroreRs 1,245 CroreRs 777 CroreRs 1,251 Crore

    The sales for Torrent Pharmaceuticals has grown steadily over the past five years, from Rs 8,004 Crore in March 2021 to Rs 11,516 Crore in March 2025. The net profit has also increased significantly, rising from Rs 1,251 Crore in March 2021 to Rs 1,911 Crore in March 2025.

    Consolidated Income Statement (Quarterly)

    Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024
    SalesRs 3,178 CroreRs 2,959 CroreRs 2,809 CroreRs 2,889 CroreRs 2,859 Crore
    Other IncomeRs -37 CroreRs -18 CroreRs 33 CroreRs -16 CroreRs 24 Crore
    Total IncomeRs 3,141 CroreRs 2,941 CroreRs 2,842 CroreRs 2,873 CroreRs 2,883 Crore
    Total ExpenditureRs 2,347 CroreRs 2,220 CroreRs 2,094 CroreRs 2,148 CroreRs 2,152 Crore
    EBITRs 794 CroreRs 721 CroreRs 748 CroreRs 725 CroreRs 731 Crore
    InterestRs 56 CroreRs 56 CroreRs 57 CroreRs 64 CroreRs 75 Crore
    TaxRs 190 CroreRs 167 CroreRs 188 CroreRs 208 CroreRs 199 Crore
    Net ProfitRs 548 CroreRs 498 CroreRs 503 CroreRs 453 CroreRs 457 Crore

    The sales for Torrent Pharmaceuticals has shown a fluctuating pattern over the past five quarters, with a recent increase from Rs 2,859 Crore in June 2024 to Rs 3,178 Crore in June 2025. The net profit has also experienced fluctuations, with a increase from Rs 457 Crore in June 2024 to Rs 548 Crore in June 2025.

    Consolidated Cash Flow

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Operating ActivitiesRs 2,585 CroreRs 3,266 CroreRs 2,368 CroreRs 1,802 CroreRs 2,010 Crore
    Investing ActivitiesRs -540 CroreRs -167 CroreRs -2,415 CroreRs -196 CroreRs -449 Crore
    Financing ActivitiesRs -2,297 CroreRs -2,779 CroreRs 77 CroreRs -1,781 CroreRs -1,656 Crore
    OthersRs -8 CroreRs 8 CroreRs 79 CroreRs 0 CroreRs 5 Crore
    Net Cash FlowRs -261 CroreRs 326 CroreRs 110 CroreRs -174 CroreRs -89 Crore

    Consolidated Balance Sheet

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Share CapitalRs 169 CroreRs 169 CroreRs 169 CroreRs 84 CroreRs 84 Crore
    Reserves & SurplusRs 7,421 CroreRs 6,686 CroreRs 6,028 CroreRs 5,868 CroreRs 5,752 Crore
    Current LiabilitiesRs 4,717 CroreRs 5,425 CroreRs 5,447 CroreRs 4,415 CroreRs 4,891 Crore
    Other LiabilitiesRs 2,681 CroreRs 2,779 CroreRs 3,366 CroreRs 2,731 CroreRs 3,345 Crore
    Total LiabilitiesRs 14,989 CroreRs 15,060 CroreRs 15,011 CroreRs 13,099 CroreRs 14,074 Crore
    Fixed AssetsRs 8,086 CroreRs 8,160 CroreRs 8,549 CroreRs 6,792 CroreRs 7,612 Crore
    Current AssetsRs 5,622 CroreRs 5,611 CroreRs 5,329 CroreRs 5,294 CroreRs 5,523 Crore
    Other AssetsRs 1,281 CroreRs 1,288 CroreRs 1,133 CroreRs 1,012 CroreRs 938 Crore
    Total AssetsRs 14,989 CroreRs 15,060 CroreRs 15,011 CroreRs 13,099 CroreRs 14,074 Crore
    Contingent LiabilitiesRs 465 CroreRs 575 CroreRs 619 CroreRs 505 CroreRs 324 Crore

    Financial Ratios

    Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021
    Basic EPS (Rs.)56.4748.9436.7945.9373.98
    Diluted Eps (Rs.)56.4748.9436.7945.9373.98
    Book Value /Share (Rs.)224.27202.57183.13351.75344.90
    Dividend/Share (Rs.)32.0028.0022.0048.0035.00
    Face Value55555
    Gross Profit Margin (%)32.5131.9330.0130.8831.69
    Operating Margin (%)25.6124.3922.6623.1023.47
    Net Profit Margin (%)16.5915.4412.949.1315.63
    Return on Networth (%)25.1724.1520.0913.0521.44
    ROCE (%)28.7127.1622.7922.6320.46
    Return On Assets (%)12.7510.998.295.938.89
    Current Ratio (X)1.191.030.981.201.13
    Quick Ratio (X)0.650.610.570.640.58
    Debt to Equity (x)0.400.570.850.670.83
    Interest Coverage (X)14.849.698.6610.307.19
    Asset Turnover Ratio (%)0.770.710.680.530.50
    Inventory Turnover (X)4.700.740.630.680.70
    3 Yr CAGR Sales (%)16.3415.7710.085.3015.67
    3 Yr CAGR Net Profit (%)56.8215.0310.2433.4635.87
    P/E (x)57.1653.1441.7830.3917.20
    P/B (x)14.4212.848.407.957.37
    EV/EBITDA (x)29.8926.6019.6619.3818.62
    P/S (x)9.518.215.415.565.37

    Torrent Pharmaceuticals announced a final dividend of Rs 6 per share (120%) with effective date as 20 Jun, 2025. Also, the company announced an interim dividend of Rs 26 per share (520%) with effective date as 31 Jan, 2025.

    Torrent Pharmaceuticals had a bonus issue with ratio 1:1, ex-bonus date was 08 Jul, 2022.

    Torrent Pharmaceuticals had a stock split, with new face value of Rs 5 from old face value of Rs 10. Ex-split date was 20 Feb, 2006.

    Moneycontrol analysis was bullish on the stock as of 2025-09-08.

    Shares of Torrent Pharmaceuticals declined by 2.01% to Rs 3,570 in Wednesday's session, reflecting a shift in investor sentiment.

    Alpha Desk
    first published: Sep 10, 2025 01:51 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347